Dexcom Strategy and Business Model

Executive Overview

Dexcom is a diabetes-technology company focused on continuous glucose monitoring (CGM), not a broad medtech conglomerate. Its core products combine wearable sensors, electronics, mobile apps, cloud-based data sharing, and interoperability with insulin-delivery systems. Founded in 1999 and headquartered in San Diego, California, Dexcom sells primarily into the diabetes market, with the United States still its largest geography and international markets an important growth lever. Revenue in FY2024 was $4.03B.

Dexcom’s strategy is to make CGM a standard tool across a larger share of the diabetes population by improving ease of use, widening payer coverage, expanding pharmacy access, and lowering cost through scale and manufacturing efficiency. The rollout of G7, the transition from the legacy G6 installed base, and the March 2024 U.S. Food and Drug Administration clearance of Stelo, an over-the-counter CGM for adults not using insulin, show how Dexcom is trying to move beyond its traditional intensive-insulin user base. That makes Dexcom both a medical-device company and a data-enabled care platform whose economics depend heavily on repeat sensor use, reimbursement, high product reliability, and durable customer retention.

Dexcom at a Glance

Logo
Common name	Dexcom
Full legal name	DexCom, Inc.
Headquarters	San Diego, California, United States
Ownership	Public company listed on Nasdaq; no controlling shareholder disclosed in 2024 public filings
Ticker	DXCM
Exchange	NASDAQ
Market Cap	$26.58B
Revenue (FY2024)	$4.03B
Founding / major historical milestones	Founded in 1999; initial public offering in 2005; built successive CGM platforms including G4, G5, G6, and G7; Stelo received U.S. FDA clearance in March 2024
Industry or industries	Medical devices; diabetes technology; digital health
Key products or services	Continuous glucose monitoring systems, related sensors and receivers, mobile software, cloud data-sharing tools, and device integrations
Geographic footprint	United States and a broad set of international markets across Europe, Asia-Pacific, the Middle East, and other regions through direct operations and distributors
Business segments as officially reported	One reportable segment focused on the design, development, manufacturing, and commercialization of CGM systems and accessories
Company website	https://www.dexcom.com

1. What Is the Strategy of Dexcom?

Dexcom’s public communications point to a strategy best understood through the Playing to Win lens: expand CGM from a specialist diabetes device into a mainstream platform used across more patient groups, more channels, and more countries, while preserving clinical credibility and improving unit economics.

1a. What is the winning aspiration of Dexcom?

Dexcom’s winning aspiration is to make continuous glucose monitoring a standard part of diabetes care for far more people than the traditional intensive-insulin population. In its public materials, the company frames this as improving outcomes and simplifying glucose management through real-time data, alerts, and connected software. Strategically, “winning” for Dexcom means broadening CGM adoption across type 1 diabetes, insulin-using type 2 diabetes, and increasingly type 2 patients using less intensive therapy, while also extending into adjacent use cases such as over-the-counter monitoring for adults not using insulin. Financially, the company has consistently emphasized durable double-digit growth, scale benefits, and margin improvement as adoption broadens.
1b. Where does Dexcom play?

Dexcom plays in diabetes technology, specifically wearable glucose biosensing and the surrounding software and connectivity layer. It competes in prescription CGM, sells through pharmacy and durable medical equipment channels, works with payers and providers, and partners with insulin-pump and digital-health ecosystems. Geographically, it plays in the United States first but also targets large international diabetes markets where reimbursement and physician adoption are still developing. Product-wise, Dexcom has historically focused on higher-acuity diabetes users, but by 2024 it was also moving into simpler and lower-friction offerings for broader populations, including over-the-counter monitoring.
1c. How does Dexcom plan to win?

Dexcom’s plan to win rests on a combination of clinical performance, user experience, ecosystem connectivity, reimbursement access, and manufacturing scale. Its value proposition is not just that it measures glucose, but that it does so continuously, with actionable alerts, app-based usability, data sharing, and integration with automated insulin-delivery systems. Against competitors, Dexcom aims to differentiate on accuracy, reliability, trusted clinical evidence, and a premium connected experience. It also needs cost reduction and channel simplification to compete effectively in broader type 2 and cash-pay segments, which is why G7 scale-up, pharmacy access, and Stelo matter strategically.
1d. What capabilities must Dexcom have in place?

To execute that strategy, Dexcom needs strong capabilities in sensor science, electronics, algorithm development, mobile software, regulatory affairs, clinical evidence generation, quality systems, and high-volume manufacturing. It also needs payer contracting and market-access capabilities, because many end users do not pay list price directly. Commercially, Dexcom must support endocrinologists, primary care physicians, pharmacies, distributors, and international reimbursement bodies. As it expands beyond specialist diabetes care, consumer-oriented marketing and digital acquisition capabilities become more important as well.
1e. What management systems does Dexcom require?

Dexcom requires tightly run management systems around quality, regulatory compliance, product launches, supply planning, and post-market surveillance. Because this is a regulated medtech business with repeat-use consumables, execution depends on manufacturing yield, complaint handling, field performance monitoring, cybersecurity, demand forecasting, and reimbursement operations. Internally, the company also needs portfolio governance to manage the G6-to-G7 transition without disrupting supply or payer coverage, plus metrics that track new patient starts, refill behavior, attrition, channel mix, gross margin, and international market access.

2. What Are the Current Strategic Initiatives of Dexcom?

As of Dexcom’s FY2023 reporting and 2024 public commentary, the company’s most important strategic initiatives were concrete and operational rather than abstract.

Scale G7 and convert the installed base from G6. G7 is Dexcom’s flagship next-generation platform. A major initiative has been ramping supply, broadening payer and channel availability, expanding compatibility with insulin-delivery systems, and moving existing G6 users onto G7 without creating disruption.
Launch Stelo and open an over-the-counter channel. In March 2024, Dexcom received U.S. FDA clearance for Stelo, an over-the-counter CGM for adults not using insulin. This matters because it gives Dexcom an entry point into a much broader, less traditional market with different pricing, marketing, and acquisition dynamics.
Expand into type 2 diabetes beyond the most intensive users. Dexcom has been working to widen evidence, payer coverage, and commercial focus beyond type 1 and intensively managed type 2 patients. That includes basal-insulin users and, through Stelo, people not using insulin.
Grow internationally with multiple product tiers. International expansion remains a strategic priority, including the rollout of G7 and the use of the Dexcom ONE family in markets that need a simpler or more access-oriented offering.
Deepen ecosystem integrations. Dexcom’s value improves when its sensors connect smoothly with insulin pumps, automated insulin-delivery systems, and digital-health applications. Continued integration work helps both retention and competitive positioning.
Improve manufacturing efficiency and gross margin. Public commentary has repeatedly tied long-term economics to better yields, higher volumes, and more efficient manufacturing. This is especially important as Dexcom addresses broader patient groups that may be more price sensitive.
Shift more volume into convenient channels. Dexcom has been expanding pharmacy access because it can simplify onboarding and refill behavior versus more cumbersome durable medical equipment workflows.

3. What Is the Business Model of Dexcom?

Dexcom’s business model is built around a regulated, repeat-use medical technology platform. Patients do not make a one-time equipment purchase and disappear; they stay on therapy and replenish sensors on a recurring basis.

What customers actually buy: Patients and channel partners buy CGM systems that include disposable or frequently replaced sensors, receivers in some cases, and, for older platforms, transmitters. The software layer is integral to the product even when it is not separately priced.
Recurring versus one-time revenue: The model is heavily repeat-driven because sensors must be replaced regularly. Receivers and certain hardware components are more episodic. This recurring replenishment dynamic is one of the most important features of Dexcom’s economics.
How pricing power works: Dexcom has some pricing power because CGM provides clinically meaningful benefits and can become embedded in a patient’s routine. But pricing is constrained by payer formularies, reimbursement rules, competitive offerings, and channel negotiations, especially against Abbott in broader-market segments.
Why the business mix matters: Dexcom does not report a large number of segments, so mix matters more than segment labels. The mix of G7 versus G6, U.S. versus international, direct versus distributor, pharmacy versus durable medical equipment, and intensive-insulin versus broader type 2 users all affect revenue quality and margin.
What drives gross margin, operating margin, and cash generation: Gross margin depends on manufacturing yields, scale, input costs, freight, warranty and service costs, and channel mix. Operating margin also reflects sales and marketing efficiency and sustained research and development spending. Cash generation benefits from recurring sensor sales, but the business also requires investment in manufacturing capacity, inventory, regulatory work, and software infrastructure.
Revenue model: Historically, the model has been prescription and reimbursement driven, with payment flowing through pharmacy, durable medical equipment distributors, and other channel structures. Stelo adds an over-the-counter, more direct-to-consumer revenue model to the mix.

4. What Products and/or Services Does Dexcom Sell?

Dexcom sells CGM hardware and software designed to help people track glucose levels in real time and share that data with caregivers or clinicians.

Dexcom G7: The company’s flagship current-generation CGM platform and the main strategic growth product as of 2024. It is central to Dexcom’s push for easier onboarding, broader adoption, and improved manufacturing economics over time.
Dexcom G6: The prior flagship CGM platform. Even as Dexcom transitions users to G7, G6 remained commercially important because of its large installed base and established integrations.
Dexcom ONE family: A simplified offering used in certain international markets to widen access and serve reimbursement environments that may not support the company’s full premium positioning.
Stelo: Dexcom’s over-the-counter CGM, cleared by the U.S. FDA in March 2024 for adults not using insulin. Stelo is strategically important because it broadens Dexcom’s addressable market and introduces a more consumer-oriented channel.
Software and data tools: Dexcom’s apps, data-sharing features, and reporting tools such as Dexcom Clarity and Dexcom Follow are part of the value proposition. They improve stickiness, caregiver engagement, and clinical workflow relevance.
Receivers and accessories: These support the overall system but are less strategically important than the recurring sensor platform.

Dexcom does not publicly break out revenue by product line in a detailed way. Even so, the strategic picture is clear: G7 is the flagship platform for growth and cost improvement, G6 remained important during the transition, and Stelo represents the most visible new market-expansion product.

5. What Are the Key Competitors or Peers of Dexcom?

Dexcom has a relatively concentrated set of direct competitors in CGM, plus adjacent peers and substitutes that matter depending on channel and patient segment.

Abbott Laboratories: Abbott’s FreeStyle Libre family is Dexcom’s most important direct competitor in CGM. Abbott has been especially strong in pharmacy channels and broader-market positioning.
Medtronic: Medtronic competes through its Guardian and related diabetes-sensing systems, particularly in pump-integrated care pathways. It is a direct rival, although its model is more tightly linked to insulin-delivery hardware.
Senseonics / Ascensia: Eversense, marketed with Ascensia support, is a direct but niche competitor with an implantable CGM approach that differs from Dexcom’s wearable model.
Roche Diabetes Care: Roche is more of a substitute and broader diabetes-care peer than a like-for-like CGM rival in the United States, but conventional glucose-monitoring products still compete for physician attention, reimbursement budgets, and patient habits.
LifeScan: Like Roche, LifeScan is primarily a substitute rather than a pure CGM peer. Traditional blood-glucose monitoring remains relevant in lower-cost or lower-reimbursement settings.
Insulet: Insulet is not a direct CGM competitor, but it is an important adjacent diabetes-technology peer because pump and sensor ecosystems increasingly influence each other’s growth.
Tandem Diabetes Care: Tandem is also more adjacent than directly competitive. It matters because automated insulin-delivery partnerships can strengthen or weaken Dexcom’s ecosystem position.

The competitive reality is that Abbott is the clearest direct mass-market rival, Medtronic matters in integrated diabetes technology, and traditional glucose-monitoring alternatives remain substitutes where price and reimbursement are decisive.

6. What Is the Marketing Strategy of Dexcom?

Dexcom’s marketing strategy combines consumer awareness, clinician education, market-access work, and channel activation. That is somewhat different from many medical-device companies, because CGM benefits from both patient pull and physician push.

Brand marketing: Dexcom uses brand-building more visibly than many medtech firms. The aim is to make CGM feel understandable, modern, and lifestyle-compatible rather than purely clinical.
Clinician-focused marketing: Endocrinologists remain important, but broader adoption requires reaching primary care physicians, diabetes educators, and health systems. Educational marketing helps simplify prescribing and interpretation.
Payer and evidence-led marketing: Reimbursement is critical, so Dexcom’s commercial effort also includes demonstrating clinical outcomes and economic value to payers and public reimbursement bodies.
Channel marketing: Pharmacy access, distributor support, and co-marketing around compatible insulin-delivery systems all influence adoption. Channel execution is especially important during platform transitions such as G6 to G7.
Consumer acquisition for new categories: Stelo introduces a more direct consumer-growth challenge, where messaging, digital acquisition, retention, and user education may matter even more than in prescription CGM.

Marketing appears to be a meaningful differentiator for Dexcom rather than just a support function. That is because broad CGM adoption depends on trust, perceived ease of use, and awareness well beyond specialist diabetes clinics.

7. What Are the Key Customer Segments of Dexcom?

Dexcom serves several overlapping customer groups. The end user is the person wearing the sensor, but the economic and clinical decision makers are broader.

People with type 1 diabetes: This has historically been a core customer segment because continuous monitoring has clear clinical utility and high engagement.
People with insulin-using type 2 diabetes: This segment is also central, especially where CGM can improve daily management and reduce adverse events.
Broader type 2 populations: Dexcom’s strategic expansion increasingly targets basal-insulin and non-insulin users, a much larger but more price- and reimbursement-sensitive opportunity.
Caregivers and families: Shared data and remote monitoring features make caregivers an important influence on purchase and retention.
Clinicians: Endocrinologists, primary care physicians, diabetes educators, and health systems are critical because they prescribe, recommend, and interpret CGM data.
Payers and reimbursement bodies: Insurers, pharmacy benefit managers, public health systems, and similar entities strongly shape access and volume.
Channel partners: Pharmacies, durable medical equipment distributors, and international distributors matter because they are the route through which products reach many users.

Dexcom is more diversified than a single-end-market device company, but its fortunes still depend heavily on diabetes adoption and reimbursement trends. The company’s biggest strategic question is how far it can expand beyond the traditional high-acuity population without eroding economics.

8. What Is the Sales Model of Dexcom?

Dexcom uses a multi-channel sales model that reflects the structure of diabetes reimbursement and the practical need to get repeat-use products to patients reliably.

Pharmacy channel: An increasingly important route in the United States because it can simplify access, refill behavior, and patient convenience.
Durable medical equipment channel: Still relevant, especially for certain reimbursed users and legacy workflows, but often more complex from the patient’s perspective.
Direct commercial selling to clinicians and payers: Dexcom uses field and support teams to drive prescribing, training, and coverage decisions.
International direct and distributor model: In some countries Dexcom sells through its own commercial presence; in others it relies more heavily on distributors and local partners.
Emerging over-the-counter and digital path: Stelo introduces a more direct consumer-sales motion, likely supported by digital onboarding and less reliance on the traditional prescription workflow.

Channel structure matters because it shapes gross-to-net economics, the speed of patient onboarding, refill persistence, and the closeness of Dexcom’s relationship with the end user. For consultants, this is important because channel redesign can materially affect growth and margin without changing the core product.

9. In What Geographies Does Dexcom Operate?

Dexcom operates globally, with the United States as its largest market as of FY2023. The company’s headquarters and major corporate functions are in San Diego, California. It also has meaningful manufacturing capacity in the United States, including Arizona, and in Malaysia, which supports international supply and scale economics.

Commercially, Dexcom serves North America, Europe, parts of Asia-Pacific, the Middle East, and other international markets through a mix of direct country operations and distributors. Large developed markets with growing reimbursement support are especially important because they can support premium device adoption and long-term refill behavior. International expansion is strategically significant not just because it adds revenue, but because it diversifies Dexcom beyond the U.S. reimbursement environment and opens access to underpenetrated patient pools.

10. Who Are the Owners of Dexcom?

Dexcom is a publicly traded company on Nasdaq under the ticker DXCM. As of the company’s 2024 proxy materials and contemporaneous public ownership filings, Dexcom had no controlling shareholder. Ownership was concentrated in large institutional investors, including major asset managers such as The Vanguard Group and BlackRock, alongside a broad base of mutual funds, index funds, and other institutions.

11. How Is Dexcom Organized?

Officially, Dexcom reports one operating and reportable segment. That reporting structure reflects the integrated nature of its business: hardware, software, manufacturing, clinical evidence, and commercialization all support a single CGM platform strategy rather than a loose portfolio of unrelated businesses.

In practical terms, Dexcom appears organized around core functions such as research and development, manufacturing and operations, quality and regulatory, global commercial, reimbursement and market access, and corporate support functions. Internally, product-platform decisions still matter a great deal, particularly the G6-to-G7 transition and international product-tiering, even though they are not disclosed as separate segments.

12. How Does Dexcom Operate?

On a day-to-day basis, Dexcom operates as a tightly integrated medical-device and digital-platform company. Value creation depends on keeping product performance high, supply reliable, software usable, and reimbursement pathways open.

Design and clinical validation: Dexcom develops sensor platforms, algorithms, and software, then validates them through clinical and regulatory processes.
Manufacturing and quality control: It manufactures sensors, electronics, applicators, receivers, and related components under regulated quality systems.
Demand planning and fulfillment: It must match inventory and production with channel demand across pharmacy, durable medical equipment, and international distribution.
Commercial execution: The company works with prescribers, payers, pharmacies, and distributors to start new patients and maintain access.
User support and retention: Because the business is repeat-driven, onboarding, education, data sharing, customer support, and refill continuity matter directly to economics.
Software and ecosystem management: Dexcom must maintain apps, cloud services, cybersecurity, and integrations with compatible devices and digital-health platforms.

The hardest operational challenges are typically manufacturing scale-up, product-transition management, regulatory reliability, and serving a growing installed base without harming user experience.

13. What Are the Growth Opportunities for Dexcom?

Dexcom’s most plausible growth opportunities are visible in its public strategy and in the economics of the CGM market.

Broader type 2 penetration: This is the largest obvious opportunity. Dexcom has historically served higher-acuity users, but much larger patient pools exist in less intensive type 2 care.
Over-the-counter expansion through Stelo: Stelo creates a path into adults not using insulin and opens a more consumer-like acquisition model.
International growth: Many countries remain underpenetrated for CGM, especially where reimbursement is improving.
Platform integrations: More connections with insulin pumps, automated insulin-delivery systems, and digital-care workflows can improve both new customer acquisition and retention.
Primary care adoption: Moving beyond endocrinology is a major volume lever because primary care physicians manage a large share of the diabetes population.
Cost reduction and margin-enabled expansion: Better manufacturing efficiency can support growth indirectly by making Dexcom more competitive in price-sensitive segments.
Adjacent biosensing and health-monitoring use cases: Public moves such as Stelo suggest Dexcom sees value in broadening beyond its historical reimbursement-defined niche.

The main constraints are reimbursement, price competition, physician workflow complexity, manufacturing execution, and the need to maintain clinical credibility while moving into broader and potentially lower-priced markets.

14. What Is the History of Dexcom?

Dexcom was founded in 1999 in San Diego by Scott Glenn, John Burd, and Lauren Otsuki. The company was created to develop continuous glucose monitoring technology at a time when diabetes management still depended heavily on intermittent fingerstick testing.

Dexcom went public in 2005, giving it capital to build out clinical, regulatory, and manufacturing capabilities. Over time, it introduced successive CGM generations that improved accuracy, usability, connectivity, and form factor. Products such as G4 and G5 helped establish Dexcom’s reputation among intensive diabetes users, while G6 became a major commercial platform and strengthened the company’s role in connected diabetes care.

The next major step was G7, which received U.S. regulatory clearance in late 2022 and began rolling out commercially in 2023. In March 2024, Dexcom received FDA clearance for Stelo, an over-the-counter CGM for adults not using insulin, signaling a meaningful broadening of the company’s target market. Historically, Dexcom’s growth story has been driven more by organic product development and market expansion than by large-scale acquisitions.

15. What Are the Key Suppliers to Dexcom?

Suppliers matter materially to Dexcom because CGM products require precise components, regulated manufacturing inputs, and reliable logistics. Dexcom has disclosed dependence on single-source or limited-source suppliers for some materials and components, which is strategically important during new-product ramps.

Sensor materials and specialized components: These include electrochemical elements, membranes, adhesives, and other materials that affect performance and wearability.
Electronics suppliers: Printed circuit boards, chips, batteries, and related electronic parts are important for transmitters, integrated devices, and receivers.
Plastics, applicator, and packaging vendors: Device housings, applicator components, sterile or protective packaging, and labeling suppliers support the finished product.
Manufacturing equipment and tooling partners: Automated lines and precision tooling can become bottlenecks when a product such as G7 is ramping quickly.
Logistics and distribution partners: Given repeat replenishment, reliable warehousing and delivery are commercially important, not just operationally convenient.

Supplier structure matters because any disruption can affect patient continuity, channel fill rates, and gross margin at the same time.

16. What Are the Key Brands Owned by Dexcom?

Brand is important for Dexcom because trust, ease of use, and clinical credibility are central to adoption and retention.

Dexcom: The corporate brand stands for CGM expertise and connected diabetes management. It is the main trust mark across patients, caregivers, clinicians, and channel partners.
Dexcom G7: The flagship current-generation brand, positioned around simplicity, smaller form factor, and next-generation usability.
Dexcom G6: A legacy but still commercially important brand during the platform transition, especially where installed-base continuity and integrations matter.
Dexcom ONE: An access-oriented brand used in certain international markets to broaden reach.
Stelo: A new over-the-counter brand that signals Dexcom’s move toward a broader consumer audience.
Dexcom Clarity and Dexcom Follow: Software sub-brands that reinforce the ecosystem by supporting data interpretation and caregiver connectivity.

For Dexcom, branding is not separate from the product; it is tied closely to clinical trust, usability, and channel acceptance.

17. How Does the Supply Chain of Dexcom Function?

Dexcom’s supply chain is strategically important because it supports a high-volume, repeat-use medical product with strict quality requirements. The company is not simply shipping durable equipment; it is managing recurring replenishment at scale.

Sourcing: Dexcom procures specialized sensor materials, electronic components, plastics, packaging, and tooling.
Manufacturing: It converts those inputs into sensors, integrated devices, receivers, and accessories under regulated production and quality-control processes.
Inventory and allocation: It must hold enough inventory to support recurring patient use while managing product transitions and avoiding obsolescence.
Channel fulfillment: Product then moves through pharmacy, durable medical equipment, and international distribution channels.
Customer continuity: Because sensors are replenishment products, service levels directly affect adherence and revenue retention.

Supply-chain reliability matters strategically for three reasons: it protects patient outcomes, it supports new-product conversions such as G7, and it influences gross margin through yield, freight, inventory, and service costs.

18. What Is the Technology Strategy of Dexcom?

Technology is central to Dexcom’s competitiveness. The company’s strategy is not just to manufacture sensors, but to combine biosensing hardware, algorithms, software, connectivity, and interoperability into a trusted platform.

Improve the sensor platform: Smaller form factor, easier insertion, reliable wear, and better user experience are key technology goals.
Strengthen software and data usability: Apps, alerts, reporting, caregiver sharing, and cloud connectivity make the device more useful than a stand-alone sensor.
Expand interoperability: Dexcom has leaned into compatibility with insulin pumps and connected diabetes systems, which increases ecosystem value and switching costs.
Support lower-cost scale: Manufacturing technology and automation matter because the ability to address broader populations depends partly on cost structure.
Maintain reliability and cybersecurity: A connected medical device must perform consistently and protect patient data.

In Dexcom’s case, technology is both an internal enabler and part of the customer offering. That makes product engineering, software development, and manufacturing automation tightly linked rather than separate agendas.

19. What Is the R&D Strategy of Dexcom?

R&D is a core strategic function for Dexcom. The company’s historical success has come from iterating the CGM platform rather than standing still on a mature installed base.

Advance next-generation sensor performance: Dexcom continues to invest in accuracy, wearability, form factor, and ease of use.
Reduce cost as well as improve function: For a company trying to reach broader type 2 and over-the-counter markets, cost-oriented R&D matters almost as much as feature-oriented R&D.
Generate clinical evidence: New patient populations, reimbursement pathways, and product claims require ongoing studies and regulatory support.
Broaden indications and use cases: Dexcom’s 2024 Stelo clearance shows that R&D is being used to widen the addressable market, not just refresh the existing franchise.
Support ecosystem compatibility: R&D also underpins device integrations, data-sharing features, and software improvements that increase retention.

The company’s R&D agenda appears designed to preserve Dexcom’s premium clinical reputation while making the platform easier to access, easier to scale, and more relevant to broader user groups.

20. How Companies Like Dexcom Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Dexcom engage Umbrex when they need talent with the training those firms provide but do not need a full consulting team with all the overhead. Umbrex consultants work across Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI. For a company like Dexcom, the most valuable projects are usually tightly scoped efforts tied to growth, channel execution, manufacturing scale, and portfolio decisions.

G7 conversion program support: Build a fact base and execution plan for converting G6 users to G7 across payers, channels, and compatible-device partners.
Stelo go-to-market design: Define target segments, digital acquisition strategy, retention journeys, pricing architecture, and performance metrics for an over-the-counter launch.
Type 2 market expansion strategy: Segment the non-intensive diabetes opportunity, size priority cohorts, and identify the most attractive payer and provider pathways.
International market prioritization: Evaluate which countries offer the best balance of reimbursement potential, competitive intensity, and channel readiness for G7 and Dexcom ONE.
Pharmacy and durable medical equipment channel optimization: Redesign channel economics, onboarding, refill workflows, and service levels to improve growth and gross margin.
Manufacturing cost-down and yield improvement: Support operations teams on line balancing, bottleneck analysis, plant-network decisions, and scale-up economics.
Sales force and account coverage redesign: Rework territory models and account prioritization as Dexcom expands beyond endocrinology into primary care and broader type 2 populations.
Payer contracting and access analytics: Analyze reimbursement economics, formulary positioning, gross-to-net performance, and evidence priorities by customer segment.
Supply-chain planning upgrade: Improve sales and operations planning, inventory policy, and product-allocation logic during fast growth and platform transitions.
Product portfolio and innovation roadmapping: Help leadership prioritize R&D bets across next-generation CGM, software features, ecosystem partnerships, and adjacent biosensing opportunities.